Abstract: Retreatment of HCV G-1 DAA-failures with Ombitasvir/Paritaprevir/r, Dasabuvir, and Sofosbuvir—F Poordad et. al
Source: The Liver Conference – Late Breaker – 20
Results and Conclusions
The investigators evaluated the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir plus sofosbuvir in direct-acting antiviral-experienced patients with HCV genotype 1 with and without cirrhosis.
- Two patients with genotype 1b patients received the above therapy without ribavirin for 12 weeks. The cure rate was 100% (2 of 2 patients)
- Fourteen patients with genotype 1a with no cirrhosis received the above therapy plus ribavirin for 24 weeks. The cure rate was 92% (12 of 13 patients) one patient was HCV RNA detectible.
One genotype 1a patient without cirrhosis had detectable RNA (viral load) at week 4—their treatment duration was extended to 24 weeks. There was one treatment discontinuation, but it was not related to the study drug and the patients achieved a cure. The most common side effects were headache, fatigue, diarrhea and insomnia.
- Six patients with genotype 1a with cirrhosis received the above therapy with ribavirin for 24 weeks. The cure rate was 100% (6 of 6 patients)
The Bottom Line
A cure rate of 92% to 100% is very encouraging in this difficult to treat population.
This combination of drugs to hit treatment related RAVs hard is a good strategy. However, more clinical trials are needed to find out if this approach will work in other HCV treatment RAVs.
Labels: Abbvie, HCV Retreatment, RAVs, sofosbvir, Viekira Pak